Xeris Biopharma Inc.
XERS | NASDAQ
$8.80
+$0.60 (+7.32%)
At close: Sep 21, 2026, 4:00 PM ET
$8.84
+$0.04 (+0.43%)
Pre-market:
Sep 22, 2026, 8:59 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M | 20.44M |
Cost of Revenue | 53.41M | 36.83M | 28.65M | 22.63M | 13.32M | 9.33M |
Gross Profit | 238.43M | 166.24M | 135.27M | 87.61M | 36.27M | 11.11M |
Operating Income | 24.9M | -33.65M | -44.01M | -81.94M | -115.16M | -83.55M |
Interest Income | 4.74M | 5.32M | 4.75M | 2.58M | 313K | 4.47M |
Pretax Income | 554K | -57.1M | -63.5M | -96.08M | -122.73M | -91.25M |
Net Income | 554K | -54.84M | -62.26M | -94.66M | -122.73M | -91.14M |
Selling & General & Admin | 182.37M | 163.48M | 146.1M | 137.75M | 125.72M | 73.73M |
Research & Development | 31.17M | 25.56M | 22.34M | 20.97M | 25.16M | 20.92M |
Other Expenses | n/a | 10.84M | 10.84M | 10.84M | 550K | n/a |
Operating Expenses | 213.54M | 199.88M | 179.28M | 169.55M | 151.43M | 94.65M |
Interest Expense | 29.08M | 33.18M | 26.61M | 14.1M | 7.18M | 7.36M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 266.95M | 236.72M | 207.92M | 192.19M | 164.75M | 103.98M |
Income Tax Expense | n/a | -2.27M | -1.25M | -1.42M | n/a | -110K |
Shares Outstanding (Basic) | 160.43M | 146.77M | 137.67M | 135.63M | 79.03M | 42.64M |
Shares Outstanding (Diluted) | 172.74M | 146.77M | 137.67M | 135.63M | 79.03M | 42.64M |
EPS (Basic) | 0 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 |
EPS (Diluted) | 0 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 |
EBITDA | 12.71M | -13.99M | -23.74M | -69.31M | -113.67M | -79.12M |
EBIT | 554K | -26.62M | -36.9M | -81.98M | -115.55M | -80.59M |
Depreciation & Amortization | 12.16M | 12.63M | 13.16M | 12.67M | 1.88M | 1.47M |
Add to Watchlist
Select watchlists to add or remove XERS